Psychedelic Stocks Universe Up Only 0.2% On Friday
31 biopharmaceutical companies are now involved in the research and development of psychedelic compounds to treat mental health issues such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. This article tracks the performance of 15 of them in the munKNEE Psychedelic Stocks Index. [TM Editors Note: Many of the companies mentioned in this article are penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.]
Index Inclusion Criteria
- a market capitalization between US$10M and US$200M
- a stock that trades between US$0.10/share and US$2/share
Below are the 15 eligible companies in the munKNEE Psychedelic Stocks Index and their performance on Friday, December 18th in descending order. Yesterday's performance for each is in brackets.
- Psyched Wellness (DCNPF) +6.7% (+4.0%)
- Hollister (HSTRF) +5.5% (+8.2%)
- Champignon (SHRMF) +5.3% (+10.6%)
- Mind Cure (MCURF) +4.3% (+5.2%)
- Better Plant (VEGGF) +4.3% (-8.4%)
- Silo Pharma (SILO) +3.2% (+3.3%)
- Seelos (SEEL) +0.7% (+4.9%)
- Mydecine (MYCOF) N/C (+5.2%)
- Cybin (CLXPF) -2.1% (+1.6%)
- Jaguar (JAGX) -3.5% (-16.3%)
- Numinus (LKYSF) -4.1% (+5.2%)
- Red Light (TRUFF) -4.3% (+3.5%)
- Revive (RVVTF) -4.5% (N/C)
- Havn (HAVLF) -6.0% (-1.5%)
- Nova Mentis (LIBFF) -10.1% (N/C)
The average performance of the above 15 psychedelic drug stocks on Friday was -1.1%. To avoid duplication please refer to a previous article (see here) in which I provided introductory paragraphs on each of the above constituents.
NOTE: The 3 largest psychedelic drug stocks in the sector were, on average, up 0.9% vs. +0.6% on Thursday. They are not included in the Index because they either trade in excess of $2/share and/or have a market cap in excess of $200M, since their inclusions would make a comparative analysis and Index averages meaningless. For the record, below are their Friday performances with their Thursday performances for yesterday in brackets:
The remaining 13 stocks in this fledgling, yet burgeoning, sector were down 2.6%, on average, on Friday. They are not eligible for inclusion in the munKNEE Psychedelic Stocks Index but are worth watching closely (see a previous article on the subject here) with the sector starting to gain considerable traction. They are as follows:
- Aion (CNSX:AION), Codebase (BKLLF), Ehave (EHVVF), Graph Blockchain (REGRF), Lobe Sciences (GTSIF), New Wave (TRMNF), Thoughtful Brands (PEMTF), Entheon (ENBI), Core One (CLABF), Newscope-PharmaTher (PHRM) and Nutritional High (SPLIF), Pure Extracts (PULL) and Tryp Therapeutics (TRYP).
Please note that Minerco (MINE) has been removed from the list as it is trading below $0.01/share on very spotty volume and Tryp Therapeutics (CNSX:TRYP), which was just listed on Friday, has been added.
In sum total, the entire 31 stocks were up 0.2%, on average, on top of +0.8% Thursday.
Visit munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample more